IP Library › Granted Patent US 12,391,927
Granted Patent B2
US 12,391,927 · App. 16/761,561 · Granted Aug 19, 2025

Multi-chimeric cell and therapy for transplantation and treatment of immune deficiencies and genetic disorders

Inventor: Maria Siemionow (Chicago, IL)
Assignee: The Board of Trustees of the University of Illinois
C12N5/16A61K35/28A61K35/34A61K40/10A61K40/22A61K40/416A61K40/418C12N5/0605C12N5/0634A61K2035/122A61K2035/124A61K2239/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,927
App. No.
16/761,561
Granted
Aug 19, 2025
Kind
B2
Abstract

A multi-chimeric cell created by ex vivo fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells, or a combination thereof, from three or more different donors is provided, as is the use of these cells in transplant therapy and treatment of immune deficiency and genetic disorders.

Claims (6)

1. A multi-chimeric cell comprising an ex vivo fusion of three or more cells selected from the group consisting of hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, satellite cells, and combinations thereof, from three or more different donors, wherein the multi-chimeric cell is in a pharmaceutically acceptable carrier or aqueous medium; and each of the three or more cells are labeled with a different label and the multi-chimeric cell resulting from the fusion can be isolated by cell sorting based on the presence of each of the different labels; and at least one of the three or more cells is a mesenchymal stem cell, myoblast, pericyte, or satellite cell.

2. The multi-chimeric cell of claim 1 , consisting of an ex vivo fusion of at least one hematopoietic stem cell and two or more mesenchymal stem cells.

3. The multi-chimeric cell of claim 1 , wherein the hematopoietic stem cells are isolated from bone marrow, umbilical cord blood, peripheral blood, or a combination thereof.

4. The multi-chimeric cell of claim 1 , wherein the donors are related, unrelated, or a combination thereof.

5. The multi-chimeric cell of claim 1 , consisting of an ex vivo fusion of at least one hematopoietic stem cell and two or more cells independently selected from mesenchymal stem cells and pericytes.

6. The multi-chimeric cell of claim 5 , consisting of an ex vivo fusion of a hematopoietic stem cell, a mesenchymal stem cell and a pericyte.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 3, 2021
From: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
To: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 055211/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: SIEMIONOW, MARIA
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 052571/0347 →
Continuity (2)
Provisional Application 62591397 · Nov 28, 2017
Related Publication 20200263141A1 · Aug 20, 2020
References Cited (16)
US 20030228289A1 · Siemionow · 2003 [cited by examiner]
US 20160346330A1 · Sussman · 2016 [cited by applicant]
WO WO03102126A1 · 2003 [cited by examiner]
WO WO2011140654A1 · 2011 [cited by examiner]
WO 2016201182A1 · 2016 [cited by applicant]
Gorbe et al. Myoblast proliferation and syncytial fusion both depend on connexin43 function in transfected skeletal muscle primary cultures. Experimental Cell Research 313 (2007) 1135-1148 (Year: 2007). [cited by examiner]
Cwykiel et al. Cellular Therapy Models: Ex Vivo Chimera Model by Cell Fusion. M.Z. Siemionow (ed.), Plastic and Reconstructive Surgery: Experimental Models and Research Designs. p. 593-603 (Year: 2015). [cited by examiner]
Craig et al. Expression of Thy-1 on Human Hematopoietic Progenitor Cells. J. Exp. Med. vol. 177 May 1993 1331-1342 (Year: 1993). [cited by examiner]
Tfaily et al. “In vitro and in vivo characterization of human hematopoietic chimeric cells—a novel strategy to induce tolerance in transplantation” (2016), Vascularized Composite Allotransplantation, vol. 3, 1-2: 29 (Ye… [cited by examiner]
Office communication dated May 27, 2022 in EP 18830033.9. [cited by applicant]
Cwykiel J. et al. “Characterization of Human Multi-Chimeric Cells a New Tolerance Inducing Cellular Therapy in Transplantation: A Preliminary Study” Abstracts of the 18th Congress of the European Society for Organ Trans… [cited by applicant]
Cwykiel, J. & M.Z. Siemionow (2015) “Cellular therapy models: ex vivo chimera model by cell fusion,” Plastic and Reconstructive Surgery: Experimental Models and Research Designs, Siemionow (Ed.), Springer-Verlag London,… [cited by applicant]
International Preliminary Report on Patentability in PCT/US2018/062736 dated Jun. 11, 2020. [cited by applicant]
International Search Report and Written Opinion in PCT/US2018/062736 dated Mar. 1, 2019. [cited by applicant]
Siemionow, M., J. Cwykiel & M. Madajka (2015) “Bone marrow-derived ex vivo created hematopoietic chimeric cells to support engraftment and maintain long-term graft survival in reconstructive transplantation,” The Scienc… [cited by applicant]
Siemionow, M., M. Madajka & J.Cwykiel (2012) “Application of cell-based therapies in facial transplantation,” Annals of Plastic Surgery 69(5):575-579. [cited by applicant]